%0 Journal Article
%T ¡°Cell-addictive¡± dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway
%A Hong Qing
%A LiQun Zhang
%A LinYing Liu
%A QingHu Yang
%A Xin Zhang
%A YanHui Li
%A ZhaoTan Jiang
%A ZhiGuo Lu
%A ZiXuan Chen
%J Theranostics
%D 2018
%I Ivyspring International Publisher
%R 10.7150/thno.28295
%X ¦Á-synclein (¦ÁS) aggregation is a representative molecular feature of the pathogenesis of Parkinson's disease (PD). Epigallocatechin gallate (EGCG) can prevent ¦ÁS aggregation in vitro. However, the in vivo effects of PD treatment are poor due to the obstacles of EGCG accumulation in dopaminergic neurons, such as the blood brain barrier and high binding affinities between EGCG and membrane proteins. Therefore, the key to PD treatment lies in visual examination of EGCG accumulation in dopaminergic neurons.
%K Parkinson's disease
%K dopaminergic neurons
%K EGCG
%K nanoparticles
%K ¦Á-synclein aggregation
%U http://www.thno.org/v08p5469.htm